Investor Letter to the U.S. Chamber of Commerce to Advocate for Public Policy to Reduce GHG Emissions

A key product in the effort to end TB is diagnostic testing.  More than 1 in 3 people with TB go undiagnosed, and part of the reason why is lack of access to and affordability of testing.  Last September, Cepheid, a molecular diagnostic company and subsidiary of Danaher Corporation, announced a 20% price reduction of its Xpert test […]

On January 21, ExxonMobil ($XOM) filed suit in Texas against two shareholders in an attempt to block a shareholder proposal urging the company to accelerate the reduction of greenhouse gas (GHG) emissions and to disclose new plans and timetables for these reductions.  ICCR released the following statement.

On November 15, 2023, the undersigned investors, representing $4.5 trillion in assets under management and advisement, call on U.S. companies to take steps towards the payment of a living wage to direct and contract workers, in line with international human rights standards. Long-term investments in the workforce are good for business, helping companies attract and […]

ICCR submitted this amicus curiae brief on September 21, 2023.

On August 10, 2023, members of the Interfaith Center on Corporate Responsibility (ICCR) announced they had sent letters to members of the Business Roundtable urging them to align political spending with their stated core values, to mitigate both reputational risks to the company, and broader risks to democracy. 

In a letter sent to 21 companies including Coca-Cola ($KO), Kraft ($KHC), Unilever ($UL), McDonald’s ($MCD), and Amazon ($AMZN) among other iconic brands, the investors pointed to the COVID-19 crisis and how it has exposed inequitable systems that contribute to the economic and health struggles of Black, Latinx and Indigenous communities in the U.S. The investors argue that the way food is developed and marketed to communities […]

In September of 2023, ICCR coordinated a group of investors in sending a letter to Nike to express significant concern over non-payment issues at two Nike suppliers. 

On August 31, 2023 investors released a statement voicing deep concern about lawsuits brought by pharma companies and trade groups to block the U.S. government’s ability to negotiate fair drug prices for Medicare beneficiaries.  The statement, which was endorsed by more than 30 institutional investors, is being sent to Astellas Pharma, Inc. ($ALPMY), AstraZeneca ($AZN), Bristol-Myers Squibb Company ($BMS), […]